Borosil Scientific Limited Earnings Summary — Q1 FY2027
Borosil Scientific Reports Strong Q1 Profit Growth as Glassware Segment Recovers
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue declined 25.4% sequentially in Q1 FY2027.
- Revenue of ₹107 Cr is 11.2% higher year-on-year.
- Revenue has compounded at -3.5% annualised over the last 10 quarters.
- Net profit of ₹4 Cr is 205.0% above the same quarter last year.
- Profit growth is outpacing revenue growth, pointing to positive operating leverage.
- Net profit has compounded at -31.4% annualised across the period.
- Operating margin stands at 7.9% in Q1 FY2027.
- Operating margin expanded by 286 bps year-on-year.
- Over the last two years operating margin has contracted by 151 bps.
- PBT margin is 5.6%.
- Expense growth of 7.9% remained below revenue growth of 11.2%.
- Operating profit of ₹8 Cr is 73.9% higher year-on-year.
- Operating leverage has been under pressure recently.
- 5 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 52/100 (Moderate) on the latest 10 quarters.
- Business momentum remains positive heading into the next quarter.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Stable | 107 | 143 | 121 | 107 | 96 | 129 | 101 | 103 | 104 | 116 |
| Expenses | Stable | 98 | 111 | 104 | 99 | 91 | 113 | 91 | 87 | 94 | 97 |
| Operating Profit | Volatile | 8 | 32 | 17 | 8 | 5 | 17 | 10 | 16 | 10 | 18 |
| Operating Margin | Volatile | 7.9% | 22.4% | 14.2% | 7.5% | 5.1% | 12.8% | 9.9% | 15.4% | 9.4% | 15.8% |
| Other Income | Volatile | 3 | 2 | 1 | 2 | -4 | 3 | 2 | 2 | 2 | 1 |
| Interest | Softening | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | Stable | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 |
| Profit Before Tax | Volatile | 6 | 29 | 13 | 5 | -4 | 14 | 7 | 12 | 7 | 15 |
| Tax | Volatile | 2 | 2 | 4 | 2 | 0 | 5 | 3 | 4 | 2 | 5 |
| Net Profit | Volatile | 4 | 27 | 9 | 3 | -4 | 9 | 4 | 9 | 5 | 9 |
| Net Margin | Volatile | 4.1% | 19.0% | 7.2% | 2.7% | -4.3% | 6.7% | 4.2% | 8.5% | 4.8% | 8.0% |
Key Takeaways
- Consolidated revenue for Q1 FY2027 grew 11.2% year-on-year to ₹106.75 Cr, driven primarily by the Scientific and Laboratory segment.
- The Glassware segment showed a significant turnaround, reporting a segment profit of ₹19 lakhs compared to a loss of ₹227 lakhs in the same quarter last year.
- The Scientific - Laboratory Glass & Equipment segment remains the primary revenue driver, contributing ₹66.68 Cr to the top line.
- Consolidated Net Profit jumped to ₹4.35 Cr from a loss in the base year, though it saw a sharp sequential decline from the high-base Q4 FY2026.
- The Board approved significant modifications to the ESOP schemes, increasing the maximum discount for new options from 10% to 20% to the market price.
- Consolidated margins were impacted by a Goel Scientific subsidiary loss of ₹236.18 lakhs during the quarter.
- The company maintains a strong balance sheet with standalone unallocated assets of over ₹269 Cr and a virtually debt-free status.
Management Guidance
Management remains focused on maintaining leadership in QC-intensive sectors like pharmaceuticals and biotechnology while navigating structural high inventory levels and long cash conversion cycles.
Sentiment Shift
Improving
The transition from a loss-making quarter in the previous year to a profitable one, coupled with the turnaround in the Glassware segment's profitability, indicates an improving operational trajectory.
Outlook
The outlook remains stable with a focus on 'Scientific - Laboratory Glass' as the growth engine. While the company faces high working capital intensity, its strong promoter holding and position in the pharma supply chain provide a resilient foundation.
From the Annual Report (Key Quotes)
“The aforesaid ESOP schemes are being amended mainly... to increase the maximum limit of discount percentage for grant of new Options from existing 10% to 20%.”
“Scientific - Laboratory Glass & equipment and Process System:- Comprising of items used in laboratories, production floor and research and development.”
“The meeting of the Board of Directors commenced at 3:10 p.m. (IST) and concluded at 4:15 p.m. (IST).”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Borosil Scientific Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.